Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University

Drug Profile

Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University

Alternative Names: BMP type-I receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University

Latest Information Update: 16 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vanderbilt University Medical Center
  • Class Small molecules
  • Mechanism of Action Bone morphogenetic protein receptor type I antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Research Fibrodysplasia ossificans progressiva; Musculoskeletal disorders

Most Recent Events

  • 18 Aug 2015 Early research in Fibrodysplasia ossificans progressiva in USA (unspecified route)
  • 18 Aug 2015 La Jolla receives Orphan Drug status for two bone morphogenetic protein type-1 receptor antagonists for Fibrodysplasia ossificans progressiva in USA
  • 18 Aug 2015 Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University receives Orphan Drug status for Fibrodysplasia ossificans progressiva in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top